Murine models for the evaluation of anti-HIV strategies

Transfusion Science

Volumn 17, Issue 1, 1996, Pages 89-98

  Chang, Lung Ji ^a   Zhang, Chengsheng ^a   Robinson, Deborah ^a   Dickie, Peter ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; GENE EXPRESSION; GENE THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOTHERAPY; MOUSE; NONHUMAN; PATHOGENESIS; SCID MOUSE; TRANSGENIC MOUSE; VIRUS GENE; VIRUS REPLICATION;

EID: 0029919265     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/0955-3886(95)00062-3     Document Type: Conference Paper

References (55)

1. Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots LJ, Davey V, Pantaleo G, Demarest JF, Carter C, Wannebo C, Yannelli JR, Rosenberg SA, Lane HC: Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nature Med 1995; 1:330-336.
2. + cytotoxic T lymphocytes protect human peripheral blood leukocyte-severe combined immunodeficient mice from HIV-1 infection by an HLA-unrestricted mechanism. J Immunol 1994; 153:4826-4833.
3. Yu M, Poeschla E, Wong-Staal F: Progress towards gene therapy for HIV infection. Gene Ther 1994; 1:13-26.
4. Chesebro B, Wehrly K, Maury W: Differential expression in human and mouse cells of human immunodeficiency virus pseudotyped by murine retroviruses. J Virol 1990; 64:4553-4557.
5. Clapham PR, Blanc D, Weiss RA: Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus. Virology 1991; 181:703-715.
6. Dragic T, Charneau P, Clavel F, Alizon M: Complementation of murine cells or human immunodeficiency virus envelope/CD4-mediated fusion in human/ murine heterokaryons. J Virol 1992; 66: 4794-4802.
7. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986; 47:333-348.
8. Canivet M, Hoffman AD, Hardy D, Sernatinger J, Levy JA: Replication of HIV-1 in a wide variety of animal cells following phenotypic mixing with murine retroviruses. Virology 1990; 178:543-551.
9. Spector DH, Wade E, Wright DA, Koval V, Clark C, Jaquish D, Spector SA: Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol 1990; 64:2298-2308.
10. Tersmette M, Van Dongen JJ, Clapham PR, de Goede RE, Wolvers-Tettero IL, Van Kessel AG, Huisman JG, Weiss RA, Miedema F: Human immunodeficiency virus infection studied in CD4-expressing human-murine T-cell hybrids. Virology 1989; 168:267-273.
11. Trono D, Baltimore D: A human cell factor is essential for HIV-1 Rev action. EMBO J 1990; 4155-4160.
12. Jasin M, Page KA, Littman DR: Glycosylphosphatidylinositol-anchored CD4/Thy-1 chimeric molecules serve as human immunodeficiency virus receptors in human, but not mouse, cells and are modulated by gangliosides. J Virol 1991; 65:440-444.
13. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus in human and non-human cells transfected with an infectious molecular clone. J Virol 1986; 59:284-291.
14. Levy JA, Cheng-Meyar C, Dina D, Luciw PA: AIDS retrovirus (ARV-2) clone replicates in transfected human and animal fibroblasts. Science 1986; 232:998-1001.
15. Mizrachi Y, Sternas L, Volksy DJ: The establishment of rodent cell lines persistently producing HIV-1. Virology 1992; 186:167-174.
16. Kim S, Ikeuchi K, Groopman J, Baltimore D: Factors affecting cellular tropism of human immunodeficiency virus. J Vizol 1990; 64:5600-5604.
17. Alonso A, Derse D, Peterlin BM: Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells. J Virol 1992; 66:4617-4621.
18. Hart CE, Ou C-Y, Galphin JC, Moore J, Bacheler LT, Wasmuth JJ, Petteway SR, Schochetman G: Human chromosome 21 is required for elevated HIV-1 expression in human-hamster hybrid cells. Science 1989; 246:488-491.
19. Newstein M, Lee I-S, Venturini DS, Shank PR: A chimeric human immunodeficiency virus type 1 TAR region which mediates high level trans-activation in both rodent and human cells. Virology 1993; 197:825-828.
20. Leonard J, Khillan JS, Gendelman HE, Adachi A, Lorenzo S, Westphal H, Martin MA, Meltzer MS: The human immunodeficiency virus long terminal repeat is preferentially expressed in Langerhans cells in transgenic mice. AIDS Res Hum Retroviruses 1989; 5:421-430.
21. Mehtali M, Munschy M, Ali-Hadji M, Kieny MP: A novel transgenic mouse model for the in vivo evaluation of anti-human immunodeficiency virus type 1 drugs. AIDS Res Hum Retroviruses 1992; 8:1959-1965.
22. Morrey JD, Bourn SM, Bunch TD, Jackson MK, Sidwell RW, Barrons LR, Daynes RA, Rosen CA: In vivo activation of human immunodeficiency virus type 1 long terminal repeat by UV type A(UV-A) light plus psoralen and UV-B light in the skin of transgenic mice. J Virol 1991; 65:5045-5051.
23. Khillan JS, Deen KC, Yu SH, Sweet RW, Rosenberg M, Westphal H: Gene transactivation by the Tat gene of human immunodeficiency virus in transgenic mice. Nucleic Acids Res 16:1423-1430.
24. Canard C, Zider A, Vernet M, Bennoun M, Saragosti S, Grimber G, Briand OP: In vivo activation by ultraviolet rays of the human immunodeficiency virus type 1 long terminal repeat. J Clin Invest 1990; 86:1369-1374.
25. Frucht DM, Lamperth L, Vicenzi E, Belcher JH, Martin MA: Ultraviolet radiation increases HIV-long terminal repeat-directed expression in transgenic mice. AIDS Res Hum Retroviruses 1991; 7:729-733.
26. Furth PA, Westphal H, Hennighausen L: Expression from the HFV-LTR is simulated by glucocorticoids and pregnancy. AIDS Res Hum Retrovizuses 1990; 6: 553-560.
27. Jolicouer P, LaPerriere A, Beaulieu N: Efficient production of human immunodeficiency virus proteins in transgenic mice. J Virol 1992; 66:3904-3908.
28. Thomas FP, Chalk C, Lalonde R, Robitaille Y, Jolicoeur P: Expression of human immunodeficiency virus type 1 in the nervous system of transgenic mice leads to neurological disease. J Virol 1994; 68:7099-7107.
29. Toggas SM, Masliah E, Rockenstien EM, Rail GF, Abraham CR, Mucke L: Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994; 367:188-193.
30. Vellutini C, Horschowski N, Philippon V, Gambarelli D, Nave K-A, Filippi P: Development of lymphoid hyperplasia in transgenic mice expressing the HIV tat gene. AIDS Res Hum Retroviruses 1995; 11:21-29.
31. Dickie P, Felser J, Ekhaus M, Bryant J, Silver J, Marinos N, Notkins AL: HIV-associated nephropathy in transgenic mice-expressing HTV-1 genes. Virology 1991; 185:109-119.
32. Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, Jay G: The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988; 335:606-611.
33. Brady HJ, Pennington DJ, Miles CG, Dzierzak EA: CD4 cell surface downregulation in HIV-1 Nef transgenic mice is a consequence of intracellular sequestration. EMBO J 1993; 12:4923-4932.
34. Shoeman RL, Sachse C, Honor B, Mothes E, Kaufmann M, Traub P. Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodefiency virus type 1 protease. Am J Pathol 1993; 142:221-230.
35. Kamel-Reid S, Dick JE: Engraftment of immune-deficient mice with human hematopoietic stem cells. Science 1988; 242:1706.
36. McCune JM, Ramikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL: The scid-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988; 241:1632-1639.
37. Mosier DE, Gulizia RJ, Baird SM, Wilson DB: Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335: 256-259.
38. Mosier DE, Gulizia RJ, Baird SM, Wilson DB, Spector DH, Spector SA: Human immunodeficiency virus infection of human PBL-SCID mice. Science 1991; 251:791-794.
39. Mosier DE, Gulizia RJ, MacIsaac PD, Torbett BE, Levy JA: Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science 1995; 260:689-692.
40. Namikawa R, Kaneshima H, Lieberman M, Weissman IL, McCune JM: Infection of the SCID-hu mouse by HIV-1. Science 1988; 242:1684.
41. McCune JM, Namikawa R, Shih CC, Rabin L, Kaneshima H: Suppression of HIV infection in AZT-treated SCID-hu mice. Science 1990; 247:564-566.
42. Ruprecht RM, Koch JA, Sharma PL, Armany RS: Development of antiviral treatment strategies in murine models. AIDS Res Hum Retroviruses 1992; 8:997-1011.
43. Kaneshima H, Su L, Bonyhadi ML, Connor RI, Ho DD, McCune JM: Rapidhigh, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse. J Virol 1994; 68:8188-8192.
44. Mosier DE, Gulizia RJ, MacIsaac PD, Corey L, Greenberg PD: Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp 160. Proc Natl Acad Sci USA 1993; 90:2443-2447.
45. Safrit JT, Fung SC, Andrews CA, Braun DG, Sun NC, Chang TW, Koup RA: hu-PBL-SCID mice can be protected from HTV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp 120. AIDS 1993; 7:15.
46. Murphy WJ, Kumar V, Bennet M: Rejection of bone marrow allografts by mice with severe combined immunodeficiency (SCID): evidence that natural killer cells can mediate the specificity of marrow graft rejection, J Exp Med 1987; 165:1212.
47. Taylor CW, Grogan TM, Lopez MHA, Leong SPL, Odeleye B, Feo-Zuppardi J, Hersh EM: Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency. Lab Invest 1992; 67:130-137.
48. Chang L.-J, Zhang C: Infection and replication of tat-minus human immunodeficiency viruses: genetic analyses of LTR and tat mutants in primary and long-term human lymphoid cells Virology 1995; 211:157-169.
49. Shih CC, Kaneshima H, Rabin L, Namikawa R, Sager P, McGowan J, McCune JM: Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J Infect Dis 1991; 163:625-627.
50. Moore J: The WHO and why of HIV vaccine trials. Nature 1994; 372:313-314.
51. Daniel MD, Kirchoff F, Czajak SC, Seghal PK, Desrosiers RC: Protective effects of live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258:1938-1941.
52. Ruprecht RM, Mullaney S, Bernard LD, Gama Sosa MA, Horn RC, Finberg RW: Vaccination with a live retrovirus: the nature of the protective immune response. Proc Natl Acad Sci USA 1990; 87: 5558-5562.
53. Sandhu J, Shpitz B, Gallinger S, Hozumi N: Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes. J. Immunol 1994; 152:3806-3813.
54. Leavitt MC, Yu M, Yamada O, Kraus G, Looney D, Poeschla E, Wong-Staal F: Transfer of anti-HIV ribozyme gene into primary human lymphocytes. Hum Gene Ther 1994; 5:1115-1120.
55. Yu M: Gene therapy for HIV/AIDS. Immunology 1994; 4:145-148.